Literature DB >> 15812907

Donor pretreatment using the aerosolized prostacyclin analogue iloprost optimizes post-ischemic function of non-heart beating donor lungs.

Thorsten Wittwer1, Ulrich F W Franke, Antonia Fehrenbach, Matthias Ochs, Tim Sandhaus, Alex Schuette, Stefan Richter, Neils Dreyer, Lars Knudsen, Thomas Müller, Harald Schubert, Joachim Richter, Thorsten Wahlers.   

Abstract

BACKGROUND: Ischemia-reperfusion injury accounts for one-third of early deaths after lung transplantation. To expand the limited donor pool, lung retrieval from non-heart beating donors (NHBD) has been introduced recently. However, because of potentially deleterious effects of warm ischemia on microvascular integrity, use of NHBD lungs is limited by short tolerable time periods before preservation. After intravenous prostanoids are routinely used to ameliorate reperfusion injury, the latest evidence suggests similar efficacy of inhaled prostacyclin. Therefore, the impact of donor pretreatment with the prostacyclin analogue iloprost on postischemic NHBD lung function and preservation quality was evaluated.
METHODS: Asystolic pigs (5 per group) were ventilated for 180 minutes of warm ischemia (Group 2). In Group 3, 100 microg iloprost was aerosolized during the final 30 minutes of ventilation with a novel mobile ultrasonic nebulizer. Lungs were then retrogradely preserved with Perfadex and stored for 3 hours. After left lung transplantation and contralateral lung exclusion, hemodynamics, rO2/FiO2, and dynamic compliance were monitored for 6 hours and compared with sham-operated controls (Group 1). Pulmonary edema was determined both stereologically and by wet-to-dry weight ratio (W/D). Statistics comprised analysis of variance with repeated measures and Mann-Whitney test.
RESULTS: Flush preservation pressures, dynamic compliance, inspiratory pressures, and W/D were significantly superior in iloprost-treated lungs, and oxygenation and pulmonary hemodynamics were comparable between groups. Stereology revealed a trend toward lower intraalveolar edema formation in iloprost-treated lungs compared with untreated grafts.
CONCLUSIONS: Alveolar deposition of Iloprost and NHBD lungs before preservation ameliorates postischemic edema and significantly improves lung compliance. This easily applicable innovation approach, which uses a mobile ultrasonic nebulizer, offers an important strategy for improvement of pulmonary preservation quality and might expand the pool of donor lungs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15812907     DOI: 10.1016/j.healun.2004.02.014

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  6 in total

1.  Donor pretreatment with nebulized complement C3a receptor antagonist mitigates brain-death induced immunological injury post-lung transplant.

Authors:  Qi Cheng; Kunal Patel; Biao Lei; Lindsay Rucker; D Patterson Allen; Peng Zhu; Chentha Vasu; Paulo N Martins; Martin Goddard; Satish N Nadig; Carl Atkinson
Journal:  Am J Transplant       Date:  2018-04-10       Impact factor: 8.086

2.  Effects of exogenous surfactant on the non-heart-beating donor lung graft in experimental lung transplantation - a stereological study.

Authors:  Gudrun Herrmann; Lars Knudsen; Navid Madershahian; Christian Mühlfeld; Konrad Frank; Parwis Rahmanian; Thorsten Wahlers; Thorsten Wittwer; Matthias Ochs
Journal:  J Anat       Date:  2014-02-14       Impact factor: 2.610

3.  Effects of intraoperative inhaled iloprost on primary graft dysfunction after lung transplantation: A retrospective single center study.

Authors:  Su Hyun Lee; Jin Gu Lee; Chang Yeong Lee; Namo Kim; Min-Yung Chang; Young-Chul You; Hyun Joo Kim; Hyo Chae Paik; Young Jun Oh
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

4.  Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study.

Authors:  Helene Haeberle; Stefanie Prohaska; Peter Martus; Andreas Straub; Alexander Zarbock; Gernot Marx; Manola Zago; Martin Giera; Michael Koeppen; Peter Rosenberger
Journal:  Trials       Date:  2020-03-04       Impact factor: 2.279

5.  Mesenchymal stem cell pretreatment of non-heart-beating-donors in experimental lung transplantation.

Authors:  Thorsten Wittwer; Parwis Rahmanian; Yeong-Hoon Choi; Mohamed Zeriouh; Samira Karavidic; Klaus Neef; Astrid Christmann; Tanja Piatkowski; Anke Schnapper; Matthias Ochs; Christian Mühlfeld; Thorsten Wahlers
Journal:  J Cardiothorac Surg       Date:  2014-09-02       Impact factor: 1.637

Review 6.  Review 2: Primary graft dysfunction after lung transplant-pathophysiology, clinical considerations and therapeutic targets.

Authors:  Zhaosheng Jin; Ka Chun Suen; Zhiping Wang; Daqing Ma
Journal:  J Anesth       Date:  2020-07-20       Impact factor: 2.078

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.